[Lapatinib or trastuzumab in combination with aromatase Inhibitors for hormone receptor positive/ErbB2-positive breast cancer]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Alcaraz A, Bardach A, Ciapponi A, Gonzalez L
Record ID 32014000271
Spanish
Authors' objectives:
To assess the evidence available on the efficacy, safety and coverage policy related aspects on the use of Lapatinib or Trastuzumab in combination with Aromatase Inhibitors (AI) in postmenopausal patients with ErbB2+/RH+ metastatic breast cancer.
Authors' recommendations:
The methodological quality of the evidence found is moderate. In the reviewed RCTs, the use of lapatinib or trastuzumab in combination with an AI in postmenopausal women with metastatic breast cancer has proved to be efficacious in slightly increasing the progression-free period and the rates of response. However, it did not show superiority when assessing overall survival when compared with the use of AI, thus resulting a higher number of adverse effects and a considerable increase in costs.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1530&origen_publicacion=publicaciones
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Receptor, ErbB-2
- Breast Neoplasms
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.